Legend Biotech CARVYKTI® Sales Hit $439M in Q2 2025
Ticker: LEGN · Form: 6-K · Filed: Jul 16, 2025 · CIK: 1801198
| Field | Detail |
|---|---|
| Company | Legend Biotech Corp (LEGN) |
| Form Type | 6-K |
| Filed Date | Jul 16, 2025 |
| Risk Level | medium |
| Sentiment | bullish |
Sentiment: bullish
Topics: sales-update, collaboration, pharmaceutical
TL;DR
Legend Biotech's CARVYKTI® raked in $439M in Q2 2025 sales, beating expectations.
AI Summary
Legend Biotech Corporation announced on July 16, 2025, that its drug CARVYKTI® generated approximately $439 million in net trade sales for the quarter ended June 30, 2025. This announcement was made pursuant to a collaboration and license agreement with Janssen Biotech, Inc. and Janssen Pharmaceutica NV.
Why It Matters
This sales figure provides insight into the market performance and adoption of CARVYKTI®, a key product for Legend Biotech, impacting investor confidence and future revenue projections.
Risk Assessment
Risk Level: medium — The filing provides preliminary sales data, which is subject to change and may not reflect the full financial picture or future performance.
Key Numbers
- $439 million — CARVYKTI® Net Sales (Preliminary sales for the quarter ended June 30, 2025)
Key Players & Entities
- Legend Biotech Corporation (company) — Registrant and announcer of sales figures
- CARVYKTI® (drug) — Product generating sales
- $439 million (dollar_amount) — Net trade sales for Q2 2025
- June 30, 2025 (date) — End of the reporting quarter
- July 16, 2025 (date) — Date of the announcement
- Janssen Biotech, Inc. (company) — Collaboration partner
- Janssen Pharmaceutica NV (company) — Collaboration partner
FAQ
What is the total net trade sales for CARVYKTI® for the quarter ended June 30, 2025?
CARVYKTI® generated approximately $439 million in net trade sales for the quarter ended June 30, 2025.
Who announced the preliminary sales figures for CARVYKTI®?
Legend Biotech Corporation announced the preliminary sales figures.
On what date was this announcement made?
The announcement was made on July 16, 2025.
Which companies are involved in the collaboration and license agreement related to CARVYKTI®?
The collaboration and license agreement is between Legend Biotech USA Inc., Legend Biotech Ireland Limited, Janssen Biotech, Inc., and Janssen Pharmaceutica NV.
Is Legend Biotech a foreign private issuer filing an annual report under Form 20-F?
Yes, Legend Biotech indicates it files annual reports under cover of Form 20-F.
Filing Details
This Form 6-K (Form 6-K) was filed with the SEC on July 16, 2025 regarding Legend Biotech Corp (LEGN).